Patents by Inventor Bernard Mandrand

Bernard Mandrand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6866838
    Abstract: The invention concerns composite nanospheres having a diameter ranging between about 50 and 1000 nm plus or minus 5%, preferably between about 100 and 500 nm plus or minus 5% and advantageously between 100 and 200 nm plus or minus 5%, and comprising an essentially liquid core consisting of an organic phase and inorganic nanoparticles, distributed inside the organic phase, and a skin consisting of at least a hydrophilic polymer derived from the polymerisation of at least one water soluble monomer, in particular N-alkylacrylamide or a N—N-dialkylacrylamide; conjugates derived from said nanospheres; their preparation methods and their uses.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: March 15, 2005
    Assignees: Bio Merieux, Centre National de la Recherche Scientifique
    Inventors: Olivier Mondain-Monval, Abdelhamid Elaissari, Eric Bosc, Christian Pichot, Bernard Mandrand, Jérôme Bibette
  • Publication number: 20050038234
    Abstract: The invention relates to bi-functionalised metallocenes of general formula (I) where Me=a transition metal, preferably chosen from Fe, Ru and Os, Y and Z, when identical are selected from —(CH2)n—O—, (CH2)—O—[(CH2)2—O]P— and —(CH2)q—CONH—(CH2)r—O—, or Y=—(CH2)S—NH— and Z=—(CH2)t—COO—, n=a whole number from 3 to 6 inclusive, p=a whole number from 1 to 4 inclusive, q=a whole number from 0 to 2 inclusive, r=a whole number from 0 to 2 inclusive, s=a whole number from 2 to 5 inclusive, t=a whole number from 3 to 6 inclusive, R and R?=H atoms or are protective groups used in oligonucleotide and peptide synthesis, where at least one of R or R? is protective group used in oligonucleotide and peptide synthesis and R and R? are as defined below: (i) when Z and Y are selected from (CH2)n—O—, —(CH2)—O—[(CH2)2—O]p— and —(CH2)q—CONH—(CH2)r—O—, then R and R? are protective groups used in oligonucleotide synthesis and R is a group which can leave a free OH group after deprotection, preferably a photolabile group such as mono
    Type: Application
    Filed: February 14, 2003
    Publication date: February 17, 2005
    Inventors: Carole Chaix-Bauvais, Corinne Moustrou, Aude-Emmanuelle Navarro, Hugues Brisset, Francis Garnier, Bernard Mandrand, Nicolas Spinelli
  • Patent number: 6828127
    Abstract: Disclosed is a process for transcribing RNA using a nucleotide reagent as the promoter. Such a reagent enables any type of RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of a polynucleotide matrix with a higher yield when the matrix is RNA than when said matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with said ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: December 7, 2004
    Assignee: Bio Merieux
    Inventors: Valérie Cheynet-Sauvion, Nadége Arnaud-Barbe, Guy Oriol, William T. McAllister, Bernard Mandrand, François Mallet
  • Publication number: 20040234991
    Abstract: A method for detecting at a solid support (3) complexing or hybridization between at least two basic molecules (8 and 9), one of the molecules being initially fixed on support (3), called identifying molecule (8), and the other being in solution in liquid sample (2), called target molecule (9). A solid support for detecting complexing or hybridization between at least two different molecules, a biochip incorporating the support and use of the biochip in a diagnostic test are also disclosed. The method includes: using chemical or biological element (10), specifically bound to the formed complex or hybrid; exciting the complex or the hybrid, so that chemical or biological element (10) releases light signal (11); receiving and transforming light signal (11) into chemical signal (15) at support (3), and detecting electric signal (12) derived from chemical signal (15).
    Type: Application
    Filed: January 28, 2004
    Publication date: November 25, 2004
    Inventors: Francis Garnier, Bernard Mandrand
  • Publication number: 20040176314
    Abstract: The invention concerns a genomic retroviral nucleic material, in an isolated or purified state, at least partially functional or non-functional, wherein the genome comprises a reference nucleotide sequence selected from the group including sequences of SEQ ID NOs: 1-15, their complementary sequences, and their equivalent sequences, in particular, nucleotide sequences having, for every series of 100 contiguous monomers, at least 70% and preferably at least 90% homology with the sequences of SEQ ID NOs: 1-15. The invention also concerns the application of this material.
    Type: Application
    Filed: November 21, 2003
    Publication date: September 9, 2004
    Applicant: BIO MERIEUX
    Inventors: Frederic Beseme, Jean-Luc Blond, Olivier Bouton, Bernard Mandrand, Francois Mallet, Herve Perron
  • Publication number: 20040170757
    Abstract: Process for depositing, on a substrate (1), a product of interest (2), according to a basic area (3) which has a low value, referred to as a “spot”, according to which process:
    Type: Application
    Filed: April 27, 2004
    Publication date: September 2, 2004
    Inventors: Agnes Perrin, Alain Theretz, Thierry Delair, Bernard Mandrand
  • Publication number: 20040108479
    Abstract: This invention concerns a valve (2), with at least one channel (3) running through it, allowing a fluid (F3) to be directed by transfer means within a device (1), the device (1) featuring at least one face (4), possibly flat, the valve (2) consisting of a film (7 or 16), flexible and/or which can be deformed, fixed on all or part of the face (4) of said device (1), and a film actuator (7), which enables said valve (2) to be activated or deactivated, this actuator consisting of an electrical power source.
    Type: Application
    Filed: November 25, 2003
    Publication date: June 10, 2004
    Inventors: Francis Garnier, Bernard Mandrand, Patrick Broyer, Pierre Imbaud
  • Publication number: 20030198647
    Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.
    Type: Application
    Filed: April 3, 2002
    Publication date: October 23, 2003
    Applicant: BIO MERIEUX
    Inventors: Herve Perron, Frederic Beseme, Frederic Bedin, Glaucia Paranhos-Baccala, Florence Komurian-Pradel, Colette Jolivet-Reynaud, Bernard Mandrand, Jeremy Alexander Garson, Philip William Tuke
  • Publication number: 20030186391
    Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.
    Type: Application
    Filed: May 7, 2003
    Publication date: October 2, 2003
    Applicant: BIO MERIEUX
    Inventors: Herve Perron, Frederic Beseme, Frederic Bedin, Glaucia Paranhos-Baccala, Florence Komurian-Pradel, Colette Jolivet-Reynaud, Bernard Mandrand
  • Publication number: 20030175691
    Abstract: The invention concerns a method for isolating proteins and/or protein and nucleic acid associations in a sample, comprising steps which consist in: contacting said sample and magnetic colloidal particles comprising a core and a coat wherein: the core is magnetic and is coated with at least a polymer comprising functional groups X selected among amine, hydroxyl, thiol, aldehyde, ester, anhydride, acid chloride, carbonate, carbamate, isocyanate and isothiocyanate groups or mixtures thereof, whereof at least one fraction has reacted with other functional groups of the coat, and the coat consists of a polymer bearing functional groups Z and Z′, capable of ionisation, identical or different, selected among amine, carboxylic acid, ester, anhydride, aldehyde, thiol, disulphide, &agr;-halogenocarbonyl, sulphonic acid, maleimide, isocyanate and isothiocyanate groups to form a mixture; incubating said mixture in predetermined conditions; and separating from the mixture the protein and/or protein and nucleic acid
    Type: Application
    Filed: January 13, 2003
    Publication date: September 18, 2003
    Inventors: Abdelhamid Elaissari, Bernard Mandrand, Thierry Delair, Doran Spencer, Ahmed Arkis
  • Publication number: 20030129202
    Abstract: The invention concerns an isolated mHBV having the following characteristics: (i) a genome with partly double-strand circular DNA, (ii) the genome including the Pre-S, S, C, P and X genes, (iii) the Pre-S genes coding for surface antigens, the S gene coding for a HBsAg envelope protein, the C gene coding for a HBeAg protein and aHBcAg protein, the P gene coding for a DNA reverse polymerase/transcriptase enzyme and the X gene coding for a HBxAg protein. The invention is characterised in that the gene S comprises a DNA nucleotide sequence referenced SEQ ID NO 1 and the Pre-S gene comprises a nucleotide sequence referenced SED ID NO 3. The invention also concerns DNA molecule, RNA molecule, modified surface proteins and their uses in particular for diagnostic, therapeutic and vaccine purposes.
    Type: Application
    Filed: December 16, 2002
    Publication date: July 10, 2003
    Inventors: Christian Trepo, Bernard Mandrand, Alan Kay, Isabelle Chemin, Florence Komurian-Pradel
  • Patent number: 6582703
    Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: June 24, 2003
    Assignee: Bio Merieux
    Inventors: Herve Perron, Frederic Beseme, Frederic Bedin, Glaucia Paranhos-Baccala, Florence Komurian-Pradel, Colette Jolivet-Reynaud, Bernard Mandrand
  • Patent number: 6579526
    Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: June 17, 2003
    Assignee: Bio Merieux
    Inventors: Herve Perron, Frederic Beseme, Frederic Bedin, Glaucia Paranhos-Baccala, Florence Komurian-Pradel, Colette Jolivet-Reynaud, Bernard Mandrand
  • Patent number: 6555091
    Abstract: The invention concerns a polypeptide specifically reacting with the antibodies of patients suffering from multiple sclerosis (SEP) and whereof the peptide sequence comprises at least one sequence selected among SEQ ID No. 1 to SEQ ID NO: 19, and their equivalent sequences, and the use of this polypeptide in a reagent and a kit for detecting multiple sclerosis, an immunoreactive composition and in a method for fixing, in a biological sample, antibodies characteristic and/or specific of multiple sclerosis.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: April 29, 2003
    Assignee: Bio Merieux
    Inventors: Colette Jolivet-Reynaud, Hervé Perron, Bernard Mandrand
  • Publication number: 20030039664
    Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.
    Type: Application
    Filed: November 26, 1997
    Publication date: February 27, 2003
    Inventors: HERVE PERRON, FREDERIC BESEME, FREDERIC BEDIN, GLAUCIA PARANHOS-BACCALA, FLORENCE KOMURIAN-PRADEL, COLETTE JOLIVET-REYNAUD, BERNARD MANDRAND, JEREMY ALEXANDER GARSON, PHILIP WILLIAM TUKE
  • Patent number: 6521341
    Abstract: The invention concerns magnetic and heat-sensitive particles having a predetermined size between 0.05 and 10 &mgr;m, each particle comprising: an inner composite core consisting of a solid organic or inorganic particle, containing within it a magnetic filler; an outer coati based on a polymer capable of interacting with at least a biological molecule, the outer polymer is heat-sensitive and has a predetermined low critical solubility temperature (LCST) ranging between 10 and 100° C. and preferably between 20 and 60° C. The invention also concerns methods for obtaining said particles and their uses. The particles are characterized in that there is an intermediate layer between the inner core and the outer layer isolating said inner core magnetic filler with respect to said functionalized outer layer. Said invention is particularly useful for separating proteins and/or nucleic acids.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: February 18, 2003
    Assignee: Bio Merieux
    Inventors: Abdelhamid Elaissari, Christian Pichot, Bernard Mandrand
  • Publication number: 20020155496
    Abstract: The invention concerns a saturated or unsaturated abietane derivative of general formula (I) wherein: Z is selected among —COOR5, —CONR1R2, —COONR3R4, —COR6, —CON, —COOR5, —CHOHR7, —SR8, —OR8, —CN, —CNO, —CNS, —NCO, —NCS and —R1R2CR9; wherein R1, R2, R3 and R4 represent a hydrogen atom, a C1-C10 alkyl, a C6-C20 aryl optionally substituted, a C7-C10 alkene, a C1-C10 alkyne, or an aminoacyl or peptidyl optionally substituted; or R1 and R2 or R3 and R4 together form a cycle or a heterocycle; R5 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R6 represents a hydrogen, a halogen, a C1-C10 alkyl, a C1-C10 alkene, a C1-C10 alkyne, or an aryl optionally substituted into C6-C20; R7 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; R8 represents a hydrogen, a C1-C10 alkyl, a C1-C10 alkene, or a C1-C10 alkyne; and R9 is selected among
    Type: Application
    Filed: January 30, 2001
    Publication date: October 24, 2002
    Inventors: Marie Helene Charles, Nadia Piga, Nicole Battail-Poirot, Laurent Veron, Thierry Delair, Bernard Mandrand
  • Publication number: 20020119449
    Abstract: Disclosed is a process for transcribing RNA using a nucleotide reagent as the promoter. Such a reagent enables any type of RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of a polynucleotide matrix with a higher yield when the matrix is RNA than when said matrix is DNA. This type of RNA polvmerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polvmerase and then by selecting the mutated RNA polymerase with said abilitv The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Application
    Filed: December 8, 1999
    Publication date: August 29, 2002
    Inventors: VALERIE CHEYNET-SAUVION, NADEGE ARNAUD-BARBE, GUY ORIOL, WILLIAM MCALLISTER, BERNARD MANDRAND, FRANCOIS MALLET
  • Patent number: 6403103
    Abstract: The nucleotide sequence of Tc100, a gene encoding a new antigenic protein from Trypanosoma cruzi called PTc100, is disclosed. The amino acid sequence of the PTc100 protein is also disclosed, along with the amino acid sequence of the dominant antigenic epitope of the PTc100 protein. The PTc100 protein and Tc100 gene, or a fragment thereof, modified or otherwise, can be used directly or indirectly for the detection of Trypanosoma cruzi, or for the monitoring of an infection generated by T. cruzi in man or animals.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: June 11, 2002
    Assignee: Bio Merieux
    Inventors: Glaucia Paranhos-Baccala, Mylene Lesenechal, Michel Jolivet, Bernard Mandrand
  • Publication number: 20020055185
    Abstract: The invention concerns a complex chemical compound comprising a solid carrier and at least a conjugate consisting of an organic polymer and a plurality of priming biomers. The invention also concerns the synthesis of said chemical compound for biopolymer synthesis and the use of said complex chemical compound after synthesis as ligand for amplifying or detecting and/or capturing target molecules.
    Type: Application
    Filed: February 4, 2000
    Publication date: May 9, 2002
    Inventors: CLAIRE MINARD, CAROLE CHAIX, THIERRY DELAIR, BERNARD MANDRAND